CORRESP Filing
Bio Green Med Solution, Inc.
Date: July 24, 2025 · CIK: 0001130166 · Accession: 0001641172-25-020804
AI Filing Summary & Sentiment
Reasoning
Referenced dates: July 7, 2025
Letter
VIA EDGAR Attention: Jason Drory Division of Corporation Finance Securities and Exchange Commission Office of Life Sciences Re: Cyclacel Pharmaceuticals, Inc. Draft Registration Statement on Form S-1 Submitted June 27, 2025 CIK No. 0001130166
Dear Ladies and Gentlemen,
On behalf of Cyclacel Pharmaceuticals, Inc. (the "Company"), we are writing to submit the Company's response to the comment of the staff of the Division of Corporation Finance of the Securities and Exchange Commission (the "Staff") dated July 7, 2025 (the "Comment Letter"), with respect to the above-referenced draft registration statement on Form S-1 filed on June 27, 2025 (the "Draft Registration Statement") relating to the registration under the Securities Act of 1933, as amended, of the securities of the Company. Concurrently with this submission, the Company has filed the Registration Statement (the "Registration Statement"). The response set forth below are based upon information provided to Rimon P.C.
Draft Registration Statement on Form S-1 submitted June 27, 2025
General
1. We note you entered into a share exchange agreement dated May 6, 2025, with FITTERS Diversified Berhad, a Malaysian publicly listed company ("Fitters Parent") and FITTERS Sdn. Bhd., a Malaysia private limited company and wholly-owned subsidiary of Fitters Parent ("Fitters") whereby Fitters Parent will exchange all of its ownership interest in Fitters representing 100% of all of the issued and outstanding capital shares of Fitters, for 19.99 percent of all of the issued and outstanding shares of your Common Stock. We further note your disclosure that you anticipate the transaction will "close in the second half of 2025." Please provide your analysis of whether you are required to include financial statements of the business acquired under Rule 8-04 of Regulation S-X and the related pro forma financial information.
Response : We acknowledge the Staff's comment and advise in response that the Company has revised the Registration Statement to include the include financial statements of Fitters in compliance with Rule 8-04 of Regulation S-X and the related pro forma financial information.
*****
We respectfully request the Staff's assistance in completing the review of the Registration Statement. If you have any additional questions regarding any of our responses or the revised Registration Statement, please do not hesitate to contact Debbie Klis on (202) 935-3390 of Rimon P.C.
Kindest regards,
/s/ Debbie A. Klis
Rimon P.C.
cc: Datuk Dr. Doris Wong, CEO
Show Raw Text
CORRESP
1
filename1.htm
1050
Connecticut Ave NW, Suite 500
Washington,
D.C. 20036
July
24, 2025
VIA
EDGAR
Attention:
Jason
Drory
Laura
Crotty
Division
of Corporation Finance
Securities
and Exchange Commission
Office
of Life Sciences
100
F Street, NE
Washington
DC 20549
Re:
Cyclacel
Pharmaceuticals, Inc.
Draft
Registration Statement on Form S-1
Submitted
June 27, 2025
CIK
No. 0001130166
Dear
Ladies and Gentlemen,
On
behalf of Cyclacel Pharmaceuticals, Inc. (the "Company"), we are writing to submit the Company's response to the comment
of the staff of the Division of Corporation Finance of the Securities and Exchange Commission (the "Staff") dated July 7,
2025 (the "Comment Letter"), with respect to the above-referenced draft registration statement on Form S-1 filed on June
27, 2025 (the "Draft Registration Statement") relating to the registration under the Securities Act of 1933, as amended,
of the securities of the Company. Concurrently with this submission, the Company has filed the Registration Statement (the "Registration
Statement"). The response set forth below are based upon information provided to Rimon P.C.
Draft
Registration Statement on Form S-1 submitted June 27, 2025
General
1. We
note you entered into a share exchange agreement dated May 6, 2025, with FITTERS Diversified
Berhad, a Malaysian publicly listed company ("Fitters Parent") and FITTERS Sdn.
Bhd., a Malaysia private limited company and wholly-owned subsidiary of Fitters Parent ("Fitters")
whereby Fitters Parent will exchange all of its ownership interest in Fitters representing
100% of all of the issued and outstanding capital shares of Fitters, for 19.99 percent of
all of the issued and outstanding shares of your Common Stock. We further note your disclosure
that you anticipate the transaction will "close in the second half of 2025."
Please provide your analysis of whether you are required to include financial statements
of the business acquired under Rule 8-04 of Regulation S-X and the related pro forma financial
information.
Response :
We acknowledge the Staff's comment and advise in response that the Company has revised the Registration Statement to include the
include financial statements of Fitters in compliance with Rule 8-04 of Regulation S-X and the related pro forma financial information.
*****
We
respectfully request the Staff's assistance in completing the review of the Registration Statement. If you have any additional
questions regarding any of our responses or the revised Registration Statement, please do not hesitate to contact Debbie Klis on (202)
935-3390 of Rimon P.C.
Kindest
regards,
/s/
Debbie A. Klis
Rimon
P.C.
cc:
Datuk
Dr. Doris Wong, CEO